ESSA Pharma Inc.:
Sm molecule drugs: castration-resistant prostate cancer. EPI-506, exp to enter clinic YE19 (second-gen compound). Developing compounds binding to N-terminus of AR and block signaling. MOA potentially overcomes resistance mechanisms currently seen in metastatic prostate cancer.
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by